Enzon Pharmaceuticals, Inc. (ENZN)
OTCMKTS: ENZN · Delayed Price · USD
0.0780
+0.0056 (7.75%)
Apr 23, 2024, 11:07 AM EDT - Market open
Company Description
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations.
Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.
The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002.
Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1981 |
| IPO Date | Feb 15, 1984 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Richard L. Feinstein |
Contact Details
Address: 20 Commerce Drive, Suite 135 Cranford, New Jersey 07016 United States | |
| Phone | 732-980-4500 |
| Website | enzon.com |
Stock Details
| Ticker Symbol | ENZN |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000727510 |
| CUSIP Number | 293904108 |
| ISIN Number | US2939041081 |
| Employer ID | 22-2372868 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard L. Feinstein | Chief Executive Officer, Chief Financial Officer and Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2024 | 10-K | Annual Report |
| Jan 5, 2024 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Aug 7, 2023 | 10-Q | Quarterly Report |
| Jun 14, 2023 | 8-K | Current Report |
| May 5, 2023 | 10-Q | Quarterly Report |
| Apr 20, 2023 | ARS | Filing |
| Apr 20, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 20, 2023 | DEF 14A | Other definitive proxy statements |
| Feb 16, 2023 | 10-K | Annual Report |